---
title: '5qSMA: standardised retrospective natural history assessment in 268 patients
  with four copies of SMN2'
date: '2024-02-27'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38409538/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240227170527&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: Newborn screening for 5qSMA offers the potential for early, ideally pre-symptomatic,
  therapeutic intervention. However, limited data exist on the outcomes of individuals
  with 4 copies of SMN2, and there is no consensus within the SMA treatment community
  regarding early treatment initiation in this subgroup. To provide evidence-based
  insights into disease progression, we performed a retrospective analysis of 268
  patients with 4 copies of SMN2 from the SMArtCARE registry in Germany, Austria ...
disable_comments: true
---
Newborn screening for 5qSMA offers the potential for early, ideally pre-symptomatic, therapeutic intervention. However, limited data exist on the outcomes of individuals with 4 copies of SMN2, and there is no consensus within the SMA treatment community regarding early treatment initiation in this subgroup. To provide evidence-based insights into disease progression, we performed a retrospective analysis of 268 patients with 4 copies of SMN2 from the SMArtCARE registry in Germany, Austria ...